Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of trimetazidine for prevention of trastuzumab- and chemotherapy-related cardiotoxicity in HER2-positive breast cancer
2016-002270-12Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trimetazidine in breast cancer (2 arms), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Cardiotoxicity during 24-month follow-up. Started Jun 2021; status: completed.
02
Drugs
trimetazidine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-002270-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002270-12.